Skip to main content

Latest news

Mon - 06, 06/03 - 06/2019 - 08:00

Do not hesitate to contact us if you want to meet our team during BIO International Convention 201

Wed, 05/08/2019 - 08:00

In 2015, the single interministerial fund (FUI) approved the TYROMAB (TYROsine kinase receptor Monoclonal AntiBody) project, led by a consortium o

Mon, 02/18/2019 - 08:46 - Tue, 02/01/2022 - 09:00

Elsalys Biotech SAS, a 2013 spinout from Transgene SA, achieved a significant milestone with the finding that lead candidate inolimomab (Leukotac)

Thu - 09, 11/08 - 09/2018 - 08:30

Dr Thierry Menguy, PhD, Head of mAb Development and Production Unit and co-founder of ELSALYS BIOTECH, has presented "Anti-CD160 alone or in combin

Mon - 07, 11/05 - 07/2018 - 09:00

Do not hesitate to contact us if you want to meet our team during Bio-Eu

Mon, 07/02/2018 - 15:00 - Fri, 07/02/2021 - 15:30
  • Efficacy and safety are consistently demonstrated in several in vivo preclinical models
  • Anti-CD160 is a potent inhibitor of ocular v

STAY IN TOUCH WITH OUR LATEST NEWS

Subcribe to our newsletter

This website uses cookies to track its audience and improve its content.

By continuing to browse this website, you agree to the use of such cookies.